-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
investigate -X- _ O
the -X- _ O
kinetics -X- _ O
of -X- _ O
immunoglobulin -X- _ O
M -X- _ O
( -X- _ O
IgM -X- _ O
) -X- _ O
during -X- _ O
the -X- _ O
different -X- _ O
stages -X- _ O
of -X- _ O
sepsis. -X- _ O
METHODS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
prospective -X- _ O
multicenter -X- _ O
study -X- _ O
, -X- _ O
blood -X- _ O
sampling -X- _ O
for -X- _ O
IgM -X- _ B-Intervention
measurement -X- _ I-Intervention
was -X- _ O
done -X- _ O
within -X- _ O
the -X- _ O
first -X- _ O
24 -X- _ O
hours -X- _ O
from -X- _ O
diagnosis -X- _ O
in -X- _ O
332 -X- _ B-Patient
critically -X- _ I-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
; -X- _ O
in -X- _ O
83 -X- _ O
patients -X- _ O
this -X- _ O
was -X- _ O
repeated -X- _ O
upon -X- _ O
progression -X- _ O
to -X- _ O
more -X- _ O
severe -X- _ O
stages. -X- _ O
Among -X- _ O
these -X- _ O
83 -X- _ O
patients -X- _ O
, -X- _ O
30 -X- _ O
patients -X- _ O
with -X- _ O
severe -X- _ O
sepsis -X- _ O
progressed -X- _ O
into -X- _ O
shock -X- _ O
and -X- _ O
IgM -X- _ O
was -X- _ O
monitored -X- _ O
daily -X- _ O
for -X- _ O
seven -X- _ O
consecutive -X- _ O
days. -X- _ O
Peripheral -X- _ O
blood -X- _ O
mononuclear -X- _ O
cells -X- _ O
( -X- _ O
PBMCs -X- _ O
) -X- _ O
were -X- _ O
isolated -X- _ O
from -X- _ O
55 -X- _ O
patients -X- _ O
and -X- _ O
stimulated -X- _ O
for -X- _ O
IgM -X- _ O
production. -X- _ O
RESULTS -X- _ O
: -X- _ O
Serum -X- _ B-Outcome
IgM -X- _ I-Outcome
was -X- _ I-Outcome
decreased -X- _ I-Outcome
in -X- _ I-Outcome
septic -X- _ I-Outcome
shock -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
systemic -X- _ I-Outcome
inflammatory -X- _ I-Outcome
response -X- _ I-Outcome
syndrome -X- _ I-Outcome
( -X- _ I-Outcome
SIRS -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
severe -X- _ I-Outcome
sepsis. -X- _ I-Outcome
Paired -X- _ I-Outcome
comparisons -X- _ I-Outcome
at -X- _ I-Outcome
distinct -X- _ I-Outcome
time -X- _ I-Outcome
points -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
sepsis -X- _ I-Outcome
course -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
IgM -X- _ I-Outcome
was -X- _ I-Outcome
decreased -X- _ I-Outcome
only -X- _ I-Outcome
when -X- _ I-Outcome
patients -X- _ I-Outcome
deteriorated -X- _ I-Outcome
from -X- _ I-Outcome
severe -X- _ I-Outcome
sepsis -X- _ I-Outcome
to -X- _ I-Outcome
septic -X- _ I-Outcome
shock. -X- _ I-Outcome
Serial -X- _ I-Outcome
measurements -X- _ I-Outcome
in -X- _ I-Outcome
these -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
beginning -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
early -X- _ I-Outcome
start -X- _ I-Outcome
of -X- _ I-Outcome
vasopressors -X- _ I-Outcome
, -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
distribution -X- _ I-Outcome
of -X- _ I-Outcome
IgM -X- _ I-Outcome
over -X- _ I-Outcome
time -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
greater -X- _ I-Outcome
for -X- _ I-Outcome
survivors -X- _ I-Outcome
than -X- _ I-Outcome
for -X- _ I-Outcome
non-survivors. -X- _ I-Outcome
Production -X- _ I-Outcome
of -X- _ I-Outcome
IgM -X- _ I-Outcome
by -X- _ I-Outcome
PBMCs -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
at -X- _ I-Outcome
all -X- _ I-Outcome
stages -X- _ I-Outcome
of -X- _ I-Outcome
sepsis -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
healthy -X- _ I-Outcome
controls. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Specific -X- _ O
changes -X- _ O
of -X- _ O
circulating -X- _ O
IgM -X- _ O
occur -X- _ O
when -X- _ O
patients -X- _ O
with -X- _ O
severe -X- _ O
sepsis -X- _ O
progress -X- _ O
into -X- _ O
septic -X- _ O
shock. -X- _ O
The -X- _ O
distribution -X- _ O
of -X- _ O
IgM -X- _ O
is -X- _ O
lower -X- _ O
among -X- _ O
non-survivors -X- _ O
. -X- _ O

